Literature DB >> 22452337

Why we still need randomized trials to compare effectiveness.

Laura Mauri.   

Abstract

Mesh：

Year:  2012        PMID： 22452337     DOI： 10.1056/NEJMe1202866

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  8 in total

1.  Austrian National CathLab Registry (ANCALAR): cardiac catheterization, coronary angiography (CA), and percutaneous coronary intervention (PCI) in Austria during the year 2011 (Registry Data with Audit including 2012).

Authors:  Volker Mühlberger; Conrad Kobel; Lalit Kaltenbach; Otmar Pachinger
Journal:  Wien Klin Wochenschr       Date:  2013-12-20       Impact factor: 1.704

2.  EFFICACY-TO-EFFECTIVENESS CLINICAL TRIALS.

Authors:  Harry P Selker; Sheeona Gorman; Kenneth I Kaitin
Journal:  Trans Am Clin Climatol Assoc       Date:  2018

3.  Comparing a marginal structural model with a Cox proportional hazard model to estimate the effect of time-dependent drug use in observational studies: statin use for primary prevention of cardiovascular disease as an example from the Rotterdam Study.

Authors:  Catherine E de Keyser; Maarten J G Leening; Silvana A Romio; J Wouter Jukema; Albert Hofman; M Arfan Ikram; Oscar H Franco; Theo Stijnen; Bruno H Stricker
Journal:  Eur J Epidemiol       Date:  2014-09-12       Impact factor: 8.082

4.  Renin-angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failure.

Authors:  Emmanuel Sorbets; Julien Labreuche; Tabassome Simon; Laurent Delorme; Nicolas Danchin; Pierre Amarenco; Shinya Goto; Christophe Meune; Kim A Eagle; Deepak L Bhatt; Philippe Gabriel Steg
Journal:  Eur Heart J       Date:  2014-03-09       Impact factor: 29.983

5.  To catch a killer: electronic sepsis alert tools reaching a fever pitch?

Authors:  Halley Ruppel; Vincent Liu
Journal:  BMJ Qual Saf       Date:  2019-04-23       Impact factor: 7.035

6.  Changes in the safety paradigm with percutaneous coronary interventions in the modern era: Lessons learned from the ASCERT registry.

Authors:  Alfredo E Rodríguez; Carlos Fernández-Pereira; Alfredo M Rodríguez-Granillo
Journal:  World J Cardiol       Date:  2012-08-26

7.  Rationale, design, and baseline characteristics of the CLARIFY registry of outpatients with stable coronary artery disease.

Authors:  Emmanuel Sorbets; Nicola Greenlaw; Roberto Ferrari; Ian Ford; Kim M Fox; Jean-Claude Tardif; Michal Tendera; Philippe Gabriel Steg
Journal:  Clin Cardiol       Date:  2017-05-31       Impact factor: 2.882

8.  β-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study.

Authors:  Emmanuel Sorbets; Philippe Gabriel Steg; Robin Young; Nicolas Danchin; Nicola Greenlaw; Ian Ford; Michal Tendera; Roberto Ferrari; Bela Merkely; Alexander Parkhomenko; Christopher Reid; Jean-Claude Tardif; Kim M Fox
Journal:  Eur Heart J       Date:  2019-05-07       Impact factor: 29.983
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.